Literature DB >> 20971854

Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.

Izumi Maezawa1, Pavel I Zimin, Heike Wulff, Lee-Way Jin.   

Abstract

Neuroinflammation and associated neuronal dysfunction mediated by activated microglia play an important role in the pathogenesis of Alzheimer disease (AD). Microglia are activated by aggregated forms of amyloid-β protein (Aβ), usually demonstrated in vitro by stimulating microglia with micromolar concentrations of fibrillar Aβ, a major component of amyloid plaques in AD brains. Here we report that amyloid-β oligomer (AβO), at 5-50 nm, induces a unique pattern of microglia activation that requires the activity of the scavenger receptor A and the Ca(2+)-activated potassium channel KCa3.1. AβO treatment induced an activated morphological and biochemical profile of microglia, including activation of p38 MAPK and nuclear factor κB. Interestingly, although increasing nitric oxide (NO) production, AβO did not increase several proinflammatory mediators commonly induced by lipopolyliposaccharides or fibrillar Aβ, suggesting that AβO stimulates both common and divergent pathways of microglia activation. AβO at low nanomolar concentrations, although not neurotoxic, induced indirect, microglia-mediated damage to neurons in dissociated cultures and in organotypic hippocampal slices. The indirect neurotoxicity was prevented by (i) doxycycline, an inhibitor of microglia activation; (ii) TRAM-34, a selective KCa3.1 blocker; and (iii) two inhibitors of inducible NO synthase, indicating that KCa3.1 activity and excessive NO release are required for AβO-induced microglial neurotoxicity. Our results suggest that AβO, generally considered a neurotoxin, may more potently cause neuronal damage indirectly by activating microglia in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971854      PMCID: PMC3030372          DOI: 10.1074/jbc.M110.135244

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Effects of kinase inhibitors on TGF-beta induced upregulation of Kv1.3 K+ channels in brain macrophages.

Authors:  Tom Schilling; Claudia Eder
Journal:  Pflugers Arch       Date:  2003-09-05       Impact factor: 3.657

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein.

Authors:  B A Bahr; K B Hoffman; A J Yang; U S Hess; C G Glabe; G Lynch
Journal:  J Comp Neurol       Date:  1998-07-20       Impact factor: 3.215

5.  Mature microglia resemble immature antigen-presenting cells.

Authors:  M J Carson; C R Reilly; J G Sutcliffe; D Lo
Journal:  Glia       Date:  1998-01       Impact factor: 7.452

6.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Amyloid-beta fibril formation is not necessarily required for microglial activation by the peptides.

Authors:  Sadayuki Hashioka; Akira Monji; Tadashi Ueda; Shigenobu Kanba; Hiroshi Nakanishi
Journal:  Neurochem Int       Date:  2005-10       Impact factor: 3.921

8.  Aggregation-Dependent interaction of the Alzheimer's beta-amyloid and microglia.

Authors:  F Muehlhauser; U Liebl; S Kuehl; S Walter; T Bertsch; K Fassbender
Journal:  Clin Chem Lab Med       Date:  2001-04       Impact factor: 3.694

9.  Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.

Authors:  Suzanne E Hickman; Elizabeth K Allison; Joseph El Khoury
Journal:  J Neurosci       Date:  2008-08-13       Impact factor: 6.167

10.  Properties of voltage-gated potassium currents of microglia differentiated with granulocyte/macrophage colony-stimulating factor.

Authors:  C Eder; H G Fischer; U Hadding; U Heinemann
Journal:  J Membr Biol       Date:  1995-09       Impact factor: 1.843

View more
  112 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

2.  Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease.

Authors:  Srikant Rangaraju; Marla Gearing; Lee-Way Jin; Allan Levey
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Amyloid precursor protein expression modulates intestine immune phenotype.

Authors:  Kendra L Puig; Adam J Swigost; Xudong Zhou; Mary Ann Sens; Colin K Combs
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

4.  Microglial TNF-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration.

Authors:  Yi-Ming Yang; De-Shu Shang; Wei-Dong Zhao; Wen-Gang Fang; Yu-Hua Chen
Journal:  Neurochem Res       Date:  2013-08-29       Impact factor: 3.996

5.  The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.

Authors:  Yi-Je Chen; Girija Raman; Silke Bodendiek; Martha E O'Donnell; Heike Wulff
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-13       Impact factor: 6.200

6.  Oligomeric Aβ-induced microglial activation is possibly mediated by NADPH oxidase.

Authors:  Juan Li; Jing Yu Yang; Xue Chun Yao; Xue Xue; Qing Chun Zhang; Xiao Xiao Wang; Ling Ling Ding; Chun Fu Wu
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

Review 7.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

8.  Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.

Authors:  Nofar Torika; Keren Asraf; Ella Roasso; Abraham Danon; Sigal Fleisher-Berkovich
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

9.  KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Authors:  Mengni Yi; Panpan Yu; Qin Lu; Herbert M Geller; Zhihua Yu; Hongzhuan Chen
Journal:  Mol Cell Neurosci       Date:  2016-08-24       Impact factor: 4.314

10.  APOE genotype-dependent modulation of astrocyte chemokine CCL3 production.

Authors:  Eiron Cudaback; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Glia       Date:  2014-08-04       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.